Amfetamine controlled release (orally disintegrating tablet) - Neos Therapeutics

Drug Profile

Amfetamine controlled release (orally disintegrating tablet) - Neos Therapeutics

Alternative Names: Adzenys XR-ODT; Amfetamine polistirex; Amfetamine XR-ODT - Neos Therapeutics; Amphetamine extended-release - Neos Therapeutics; Amphetamine orally disintegrating tablet - Neos Therapeutics; Amphetamine XR-ODT - Neos Therapeutics; NT-0202

Latest Information Update: 30 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neos Therapeutics
  • Class Amphetamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Trace amine-associated receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 26 Oct 2017 The US label for amphetamine extended release orally disintegrating tablets carries a black box warning related to the potential for abuse and dependence
  • 18 Oct 2017 Neos Therapeutics enters into settlement agreement with Actavis Laboratories related to ANDA patent litigation in USA
  • 15 Mar 2017 Neos Therapeutics plans three clinical trials for Attention-deficit hyperactivity disorder (In children, 4 to less than 6 years old) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top